From: Tumor metastasis to bone
Therapeutic strategy | Target and rationale for therapy |
---|---|
Recombinant OPG construct | Blocks RANKL and TRAIL pathway [69] |
Soluble RANK-Fc | Blocks the effect of RANKL without any effect on the TRAIL pathway [43-45] |
Human monoclonal antibody to RANKL (denosumab) | Blocks the effect of RANKL without any effect on the TRAIL pathway [72] |
Oligonucleotides to NF-κB, P2X7 receptor antagonists | Block the effect of NF-κB activation [97] |
Humanized anti-PTHrP monoclonal antibody | Inhibits PTHrP-mediated osteolysis via the RANKL pathway [41] |
PDGFR antagonist (ST1571, Imatinib mesylate/Gleevec) | Inhibits tumor growth and angiogenesis by inhibiting PDGFR tyrosine kinase signaling [98] |
ETA receptor inhibitor (atrasentan) | Blocks ET-1 mediated bone formation in prostate skeletal metastasis [55,58,59] |
EMD121974 (cilengitide) | Inhibits tumor-ECM interactions involved in tumor metastasis, growth, and angiogenesis [76] |
MMP inhibitors | Inhibit MMP mediated tumor growth, metastasis, and angiogenesis [99] |